Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.04) by 100 percent. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year.
RBC Capital Maintains Outperform on Lightspeed Commerce, Lowers Price Target to $30
RBC Capital analyst Daniel Perlin maintains Lightspeed Commerce (NYSE:LSPD) with a Outperform and lowers the price target from $34 to $30.
